gavin
Topics Engaged In
-
- Topic
- Voices
- Posts
- Last Post
-
-
Clinical activity and safety of the RET inhibitor pralsetinib in patients with R
Started by:
in: New Developments
- 1
- 1
- 3 years, 1 month ago
-
Final results from ClarIDHy, a global, phase 3, randomized, double-blind study o
Started by:
in: Clinical Trials
- 1
- 1
- 3 years, 1 month ago
-
Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvati
Started by:
in: Chemotherapy & More
- 1
- 1
- 3 years, 1 month ago
-
Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with FG
Started by:
in: New Developments
- 1
- 1
- 3 years, 1 month ago
-
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients
Started by:
in: New Developments
- 1
- 1
- 3 years, 1 month ago
-
Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic ch
Started by:
in: Chemotherapy & More
- 1
- 1
- 3 years, 1 month ago
-
FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangioc
Started by:
in: Chemotherapy & More
- 1
- 1
- 3 years, 1 month ago
-
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic chol
Started by:
in: Clinical Trials
- 1
- 1
- 3 years, 1 month ago
-
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinom
Started by:
in: Chemotherapy & More
- 1
- 1
- 3 years, 1 month ago
-
IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive gen
Started by:
in: New Developments
- 1
- 1
- 3 years, 1 month ago
-
Primary and secondary liver failure after major liver resection for perihilar ch
Started by:
in: Surgery, Resection & Transplant Treatment Options
- 1
- 1
- 3 years, 1 month ago
-
Thrombotic Microangiopathy in a Patient With COVID-19 Infection and Metastatic C
Started by:
in: Adverse Reactions & Side Effects
- 1
- 1
- 3 years, 2 months ago
-
Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art
Started by:
in: New Developments
- 1
- 1
- 3 years, 2 months ago
-
Clinical activity and safety of the RET inhibitor pralsetinib in patients with R